- Home
- SRAD vs AMRX Comparison
SRAD vs AMRX Comparison
Compare SRAD & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRAD | AMRX |
|---|---|---|
| Founded | 2001 | 2002 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 5.8B |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | SRAD | AMRX |
|---|---|---|
| Price | $14.70 | $18.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 16 | 5 |
| Target Price | ★ $24.31 | $15.60 |
| AVG Volume (30 Days) | ★ 1.9M | 1.8M |
| Earning Date | 04-28-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 157.89 |
| EPS | N/A | ★ 0.19 |
| Revenue | N/A | N/A |
| Revenue This Year | $24.03 | $4.48 |
| Revenue Next Year | $14.81 | $7.13 |
| P/E Ratio | ★ $49.48 | $94.32 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.66 | $7.67 |
| 52 Week High | $32.22 | $18.39 |
Technical Indicators
Market Signals| Indicator | SRAD | AMRX |
|---|---|---|
| Relative Strength Index (RSI) | 48.47 | 64.61 |
| Support Level | $14.54 | $12.46 |
| Resistance Level | $16.41 | $18.13 |
| Average True Range (ATR) | 0.55 | 0.57 |
| MACD | -0.12 | -0.05 |
| Stochastic Oscillator | 28.64 | 78.87 |
Price Performance
Historical ComparisonAbout SRAD Sportradar Group AG
Sportradar Group AG is a technology platform enabling next-generation engagement in sports, and a provider of B2B solutions to the sports betting industry. It generates revenue through two primary sources: subscription-based revenue and revenue sharing. Geographically, it operates in North America, Africa, AsiaPac & Middle East, Europe, and LATAM & Caribbean.
About AMRX Amneal Pharmaceuticals Inc.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.